Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Radiation delivered to metastatic tumors is known to cause damage to the DNA (genetic information) in the cancer cells, which causes them to die. An ATM mutation reduces cancer cells' ability to fix damage to their DNA, making it more likely that the radiation will kill ATM-mutated cancer cells. Lower doses of radiation therapy may cause fewer side effects than standard doses. In this study, researchers will observe the side effects of reduced-dose radiation therapy in patients with metastatic tumors that contain an ATM mutation and the rate at which tumors grow back (recur) after this treatment. It is hoped that lowering the radiation dose will be effective while reducing the side effects of treatment.
Radical hysterectomy via laparotomy (open surgery) is the standard surgical approach for people with early-stage cervical cancer. A radical hysterectomy involves removal of the uterus, cervix, parametria (tissue beside the cervix), and upper part of the vagina; the ovaries, fallopian tubes, and nearby lymph nodes may also be removed. With laparotomy, the operation is performed through a large incision in the abdomen.
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Osimertinib is a standard treatment for metastatic non-small cell lung cancer (NSCLC) that has a change (mutation) in the EGFR gene. Researchers think that adding chemotherapy to osimertinib could make treatment more effective.
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
The purpose of this study is to assess the safety and effectiveness of combination therapy with zanubrutinib, obinutuzumab, and venetoclax in patients newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
The purpose of this research study is to understand more about smoldering multiple myeloma (SMM). SMM is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms.
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.
Liver stereotactic ablative radiotherapy (L-SABR) is a standard treatment that uses radiation therapy to target tumors that have spread to the liver while limiting the radiation dose to surrounding organs. L-SABR may also boost the immune response.
